Back to Search
Start Over
The art of blocking ADP-ribosyltransferases ( ARTs): Nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs.
- Source :
-
FEBS Journal . Aug2013, Vol. 280 Issue 15, p3543-3550. 8p. - Publication Year :
- 2013
-
Abstract
- In 1901, the first Nobel Prize in Physiology or Medicine was awarded to Emil von Behring for his ground-breaking discovery of serum therapy: serum from horses vaccinated with toxin-containing culture medium of Corynebacterium diphtheriae contained life-saving 'antitoxins'. The molecular nature of the ADP-ribosylating toxin and the neutralizing antibodies were unraveled only 50 years later. Today, von Behring's antibody therapy is being refined with a new generation of recombinant antibodies and antibody fragments. Nanobodies, which are single-domain antibodies derived from the peculiar heavy-chain antibodies of llamas and other camelids, are emerging as a promising new class of highly specific enzyme inhibitors. In this review, we illustrate the potential of nanobodies as tools to block extracellular and intracellular ADP-ribosyltransferases ( ARTs), using the toxin-related membrane-bound mammalian ecto-enzyme ARTC2 and the actin- ADP-ribosylating Salmonella virulence plasmid factor B toxin of Salmonella enterica as examples. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1742464X
- Volume :
- 280
- Issue :
- 15
- Database :
- Academic Search Index
- Journal :
- FEBS Journal
- Publication Type :
- Academic Journal
- Accession number :
- 89079299
- Full Text :
- https://doi.org/10.1111/febs.12313